Myasthenia Gravis Market to Reach US$ 2.4 Bn by 2027, TMR Report

Prospects of approval of several pipeline drugs for the treatment and management of myasthenia gravis demonstrate profitability in the myasthenia gravis market

Albany, New York, UNITED STATES

Wilmington, Delaware, United States, July 28, 2022 (GLOBE NEWSWIRE) -- Transparency Market Research Inc.: Analysts at TMR estimate the myasthenia gravis market to clip a CAGR of 8% during the forecast period from 2019 to 2027. High prevalence of autoimmune diseases, and strong focus on introducing new therapies is fueling the growth of myasthenia gravis market.

Need to develop new therapies and medications for reducing the prevalence of myasthenia gravis is anticipated to have a positive impact on the myasthenia gravis market size. Rising healthcare expenditure combined with growing per capita income is attracting leading players in the myasthenia gravis market to invest in research and development for advanced treatments such as plasma exchange and intravenous immunoglobulin therapies.

North America stood as the frontrunner in the myasthenia gravis market in 2018, and is anticipated to remain dominant during the forecast period. Factors such as well-established healthcare infrastructure, significant R&D for new therapies, and availability of advanced treatment for a large population fuel the growth of myasthenia gravis market in the region. Additionally, early adoption of innovative technologies for drug development is likely to open growth opportunities in myasthenia gravis market in the region.

Get Exclusive PDF Sample Copy of Myasthenia Gravis Market Report –

Myasthenia Gravis Market – Key Findings of the Report

  • Clinical possibility of treatment of myasthenia gravis with medication, therapies, or surgeries alone, or in combination is driving players to invest in R&D and develop new therapies. This will shape the myasthenia gravis market outlook in the upcoming years.
  • Presence of 80 to 100 types of autoimmune diseases that are increasingly prevalent in the world is leading to the increased demand for advanced therapies. According to the American Autoimmune Related Diseases Association, at present, in the U.S., 50 million people are living with autoimmune diseases. This is driving industry players to engage in developing new products. Emerging trends in myasthenia gravis market of strong drug pipeline supported by government-funded research in several countries are expected to expand frontiers.
  • Initiatives of drug manufacturers for the development of new therapeutic targets to treat myasthenia gravis opens lucrative growth opportunities in the myasthenia gravis market. The FDA approval of Alexion Pharmaceuticals Inc. for clinical use of Solaris in the treatment of generalized myasthenia gravis is a case in point.
  • Significant investment from governments in developing countries toward modernization of healthcare is expected to increase the demand for advanced therapies. This includes intravenous immunoglobulin (IVIG) and monoclonal antibodies treatments for autoimmune diseases such as myasthenia gravis.
  • Based on treatment type, rapid immunotherapies segment held the leading share of myasthenia gravis market in 2018, and is anticipated to continue to stay at the fore during the forecast period.
  • Drug treatment segment is significant in the myasthenia gravis market, as it is the common treatment for myasthenia gravis.
  • Asia Pacific is anticipated to emerge as a key market for myasthenia gravis in the upcoming years. Large patient pool, rising healthcare expenditure in emerging economies, and rising awareness for newer therapies are creating opportunities in the myasthenia gravis market in the region.

Ask for References

Myasthenia Gravis Market – Growth Drivers

  • Need for improved clinical outcomes for the high prevalence of myasthenia gravis fuels the growth of myasthenia gravis market
  • Initiatives for the development of new products, along with government funded research activities for drug development stimulates the myasthenia gravis market

Make an Enquiry Before Buying

Myasthenia Gravis Market – Key Players

Some of the key players operating in the myasthenia gravis market are;

  • Alexion Pharmaceutical Inc.
  • CSL Behring
  • Baxter International Inc.
  • Novartis AG
  • Takeda Pharmaceutical Company
  • Avadel Pharmaceutcals PLC.
  • Grifols S.A.
  • Shire plc
  • F. Hoffmann-La Roche AG
  • Valeant Pharmaceuticals International Inc.

The myasthenia gravis market is segmented as follows;

Global Myasthenia Gravis Market, by Treatment Type

  • Drug Treatment
    • Cholinesterase Inhibitors
    • Chronic Immunomodulators
    • Monoclonal Antibodies
  • Rapid Immunotherapies
    • Plasmapheresis
    • Intravenous Immunoglobulin (Ivlg)
  • Thymectomy

Global Myasthenia Gravis Market, by Region

  • North America
    • U.S.
    • Canada

  • Europe

    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Rest of Europe

  • Asia Pacific

    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Rest of Middle East & Africa

Modernization of healthcare in terms of both infrastructure and services have pushed the healthcare industry to new heights, Stay Updated with Latest Healthcare Research Reports by Transparency Market Research:

Intravenous Immunoglobulin Market: The global intravenous immunoglobulin market is expected to reach value of US$ 20.5 Bn by the end of 2031 and to grow at a CAGR of 7.3% from 2022 to 2031.

Subcutaneous Immunoglobulin Market: The global subcutaneous immunoglobulin market was valued at US$ 4.0 Bn in 2018 and is anticipated to expand at a CAGR of 13.1% from 2019 to 2027.

Stool Secretory Immunoglobulin A Market: The global stool secretory immunoglobulin A (SIgA) market is on course to reach US$ 38 Mn by the end of 2030.

Cancer Immunotherapy Market: The global cancer immunotherapy market is expected to cross value of US$ 261.7 Bn by the end of 2031 and to grow at a CAGR of 13.6% from 2022 to 2031.

Allergy Immunotherapy Market: The global allergy immunotherapy market was valued at US$ 1.37 Bn in 2016 and is projected to expand at CAGR of 10.7% from 2017 to 2025 to exceed the US$ 3.33 Bn by 2025.

Oncolytic Virus Immunotherapy Market: The global oncolytic virus immunotherapy market is expected to cross a market value of ~US$ 2.3 Bn by the end of 2030.

HER2 Antibodies Market: The demand in the global HER2 antibodies market is projected to increment at a robust CAGR of 8.6% during the forecast period of 2017 to 2025, primarily gaining from growing awareness regarding the prevalence of HER2 positive breast cancer.

Clinical Laboratory Services Market: Increasing prevalence of infectious and chronic and infectious illnesses is likely to fuel growth of the global clinical laboratory services market.

About Transparency Market Research

Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and business consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

For More Research Insights on Leading Industries, Visit Our YouTube Channel and hit subscribe for Future Update -


Rohit Bhisey
Transparency Market Research Inc.
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453